Britain and America have secured a landmark bilateral deal that will keep zero tariffs on British medicine products entering the US market.
Key Provisions of the Deal
In exchange for the tariff guarantee, the UK has pledged to raise expenditure on pharmaceuticals through the NHS. This commitment secures that duties on these key products will remain at zero for a duration of 36 months.
This deal is in response to earlier threats to hike tariffs on branded pharmaceutical products, with figures mentioned reaching 100%.
"This agreement with the UK reinforces the global environment for innovative medicines and establishes much-needed fairness to American-British pharmaceutical trade," a release noted.
Commercial Impact
Drugs are one of the UK's most significant exports to the US, which is clearly the largest market for leading companies like GSK and AstraZeneca.
Trade data show that in the 12 months to the end of last September, the UK shipped drugs totaling £11.1bn to the US. This amount represented 17.4% of total UK exports in that period.
"This agreement safeguards work, stimulates funding and sets the stage for the UK to become a global hub for life sciences," a minister remarked.
Specific UK Commitments
The deal entails several specific commitments from the UK:
- Revised Affordability Limit: The UK will increase the affordability limit at which it deems new treatments to be prohibitively costly by 25%.
- Boosted Medicine Funding: There is a aim to increase overall public funding on treatments from 0.3% of the national economy to 0.6 percent over the coming ten years.
- Payback Limit: The percentage pharmaceutical firms must return to the NHS to control costs will be limited at fifteen percent. Last year, rebates topped twenty percent.
Broader Context
This agreement takes place against a long-running row between the pharmaceutical industry and the UK government over spending levels and NHS adoption.
These tensions were heightened by claims that American customers were charged several times more for the identical medicines than people in the Britain and the EU.
In recent months, several major pharmaceutical investments in the UK have been delayed or scrapped, while major funding commitments have been pledged toward projects in the United States.
The Science Minister stated that the NHS had to invest a greater share on drugs, noting that its expenditure on drugs had shrunk as a share of its overall budget over the last ten years.
